ÂÜÀòÂÒÂ×

Kevin McCann is an accomplished finance executive with extensive experience in the biopharmaceutical and medical device industries. Currently serving as Vice President, Americas Controller for Rare Disease at Amgen since August 2022, Kevin was recruited to lead accounting, controllership, financial operations, and procurement amidst the company’s growth. Prior to Amgen, Kevin held significant leadership roles, including Vice President at Orphazyme A/S, where financial and commercial operations were designed to support late-stage biopharma pipeline approvals. Additional experience includes Director positions at Baxter International Inc. and Shire, where Kevin oversaw FP&A, financial operations, and commercial strategies across multiple regions and business units. Kevin's career began at KPMG US as a Supervising Senior Auditor, following the completion of a Bachelor's degree in Accounting from the University of Iowa.